Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?
Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.
You may also be interested in...
Amgen Makes The Case For Growth, Dispenses With Share Buybacks
The promise of late-stage candidates and emerging markets, where it also disclosed a new deal, was the focus for management on its third quarter earnings call. Underscoring its repositioning as an innovative growth company, Amgen said it will not do further share repurchases in the next few years.
START-UP’s 2013 Life Science Venture Capital Survey: Lights, Even Exits, At The End Of A Dark Tunnel
Our third annual survey of institutional and corporate VCs arrives as life science investing reaches a crossroads. Public markets are gung ho for new biotech companies, lifting the spirits of a subset of our respondents, but VCs still face big hurdles to raise new funds.
ACA Countdown: Details Emerging On Exchanges, Medicaid Expansion
Open enrollment in state exchange plans kicks off Oct. 1 and expanded Medicaid eligibility Jan. 1, and many states offer a preliminary view of how coverage will play out under the Affordable Care Act in 2014.